There are currently 86 active clinical trials seeking participants for Lymphoma research studies. The states with the highest number of trials for Lymphoma participants are Ohio, Illinois, California and New York.
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
NCT06131801
Recruiting
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown. Primary Objectives • To determ... Read More
Gender:
ALL
Ages:
Between 0 years and 38 years
Trial Updated:
07/02/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma
Register for Updates
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
NCT06680661
Recruiting
The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT.... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/02/2025
Locations: University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Register for Updates
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
NCT03258567
Recruiting
Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments. Objectives: To see if Nivolumab slows the growth of some types of cancer or stops them from getting worse. To test the safety of the drug. Eligibility: People 12 and older who have Epstein-Barr Virus (EBV)-positive lymphoproliferative disorders or... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder, Disorders, Lymphoproliferative
Register for Updates
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
NCT05237986
Recruiting
Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically interested in learning if and how this treatment may affect the brain or your thinking skills. Objective: To learn if CAR T-cell therapy can affect how children and adults think, process, and remember... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
08/22/2025
Locations: Children s Hospital of Los Angeles, Los Angeles, California +2 locations
Conditions: Lymphoma, Leukemia
Register for Updates
Vaccine Responses in Patients With B Cell Malignancies
NCT05170399
Recruiting
Background: People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers want to learn more about vaccine responses in people with certain types of blood cancers. The findings may help develop better vaccine strategies for people with these cancers. Objective: To learn h... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphoma
Register for Updates
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
NCT05921253
Recruiting
This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/20/2025
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma +1 locations
Conditions: Breast Cancer, Lymphoma
Register for Updates
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
NCT07030699
Recruiting
The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL. This is the first time the combination of drugs is being tested.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Lymphoma
Register for Updates
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
NCT05389293
Recruiting
The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Georgetown University (Data Collection Only), Washington, District of Columbia +8 locations
Conditions: Follicular Lymphoma, Lymphoma
Register for Updates
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
NCT06510361
Recruiting
This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
Register for Updates
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
NCT04570423
Recruiting
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Gender:
ALL
Ages:
Between 1 month and 17 years
Trial Updated:
08/13/2025
Locations: New York Medical College, Valhalla, New York +3 locations
Conditions: Solid Tumors, Lymphoma
Register for Updates
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085
Recruiting
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: UC San Diego Moores Cancer Center, La Jolla, California +11 locations
Conditions: Lymphoma
Register for Updates
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
NCT01441089
Recruiting
Background: - Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: - To obtain a blood or cheek swab sample to study genetic differences that may affect cancer treatment. Eligibility: - Individuals with cancer who are being treated at the National Cancer Institute. De... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
08/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
Register for Updates